How should I manage a patient who has discontinued the combined oral contraceptive Mili (ethinyl‑estradiol) and now presents with elevated liver enzymes and periorbital swelling?

Management of Patient Who Discontinued Mili with Elevated Liver Enzymes and Periorbital Swelling

The patient should remain off Mili permanently, undergo immediate evaluation for drug-induced liver injury and angioedema, and transition to a non-estrogen contraceptive method once acute issues resolve. 1

Immediate Assessment and Management

Discontinuation is Correct and Must Be Permanent

• Mili must be discontinued immediately and permanently when liver problems develop, as acute or chronic disturbances of liver function necessitate discontinuation until markers return to normal and causation has been excluded. 1

• The periorbital swelling raises concern for angioedema, a serious adverse effect listed in the FDA labeling that requires immediate cessation of the medication and can lead to difficulty swallowing or breathing. 1

• Patients should be instructed to use non-hormonal contraception after stopping Mili when serious adverse effects occur. 1

Evaluate Severity of Liver Injury

• Check ALT, AST, alkaline phosphatase, total bilirubin, and prothrombin time to characterize the pattern and severity of hepatotoxicity. 1, 2

• Drug-induced liver injury from combined oral contraceptives containing ethinyl estradiol can range from mild transaminase elevations to severe cholestatic jaundice. 2, 3

• While most cases resolve rapidly after discontinuation, symptoms and bilirubin can paradoxically worsen for up to 3 months after stopping the medication before full recovery occurs. 3

• Liver biopsy may be considered if the diagnosis is uncertain or if liver enzymes fail to improve, though this is rarely necessary. 2

Assess for Angioedema

• Periorbital swelling in the context of combined oral contraceptive use suggests angioedema, which is explicitly listed as a serious adverse effect in Mili's labeling. 1

• Evaluate for involvement of lips, tongue, throat, or respiratory compromise requiring emergency intervention. 1

• The risk of angioedema is higher in patients with a prior history of this condition. 1

Contraindications to Restarting Mili

Absolute Contraindications Now Present

• Liver disease is an absolute contraindication to Mili and all estrogen-containing contraceptives. 1

• Patients who develop jaundice while taking combined oral contraceptives should avoid all estrogen-containing contraceptives permanently. 4

• Angioedema occurring during Mili use is also a contraindication to restarting this or similar medications. 1

Special Considerations for Hepatitis C Treatment

• If the patient requires hepatitis C treatment with ombitasvir/paritaprevir/ritonavir (with or without dasabuvir), ethinyl estradiol-containing medications are absolutely contraindicated due to risk of severe ALT elevations (>5× upper limit of normal). 1

Alternative Contraception Options

Recommended Non-Estrogen Methods

• Estrogen-containing agents should be avoided in patients with liver disease, and this patient has demonstrated hepatotoxicity. 5

• Progestin-only pills (POPs) are not associated with blood pressure elevations or significant liver effects and represent a safer hormonal option. 6

• Long-acting reversible contraceptives (LARCs) including copper or levonorgestrel IUDs are highly effective and avoid first-pass hepatic metabolism. 5

• Barrier methods should be used in combination with any non-LARC method given higher failure rates. 5

Timing of New Contraception

• Non-hormonal contraception should be initiated immediately while liver function is being evaluated. 1

• Hormonal contraception (progestin-only methods) can be considered once liver enzymes normalize and hepatotoxicity is confirmed to be resolving. 1, 4

• Patients with a history of oral contraceptive-induced liver disease who have normalized liver function tests may tolerate progestin-only methods with close monitoring, though estrogen-containing products remain contraindicated. 4

Monitoring and Follow-Up

Liver Function Monitoring

• Repeat liver function tests in 2-4 weeks to document improvement after discontinuation. 1

• Continue monitoring until complete normalization occurs, which may take several months in severe cases. 3

• If liver enzymes fail to improve or worsen despite discontinuation, investigate alternative causes of hepatotoxicity. 1

Documentation for Future Care

• Document this adverse reaction prominently in the medical record as a contraindication to all estrogen-containing contraceptives. 4

• Counsel the patient that she should inform all future healthcare providers about this reaction. 1

• First-degree relatives may be at increased risk for similar reactions and should be monitored closely if using combined oral contraceptives. 4

Common Pitfalls to Avoid

• Do not rechallenge with Mili or any estrogen-containing contraceptive, as this can cause recurrent and potentially more severe hepatotoxicity. 2, 4

• Do not assume rapid resolution—cholestatic injury can worsen for weeks to months after discontinuation before improving. 3

• Do not overlook the angioedema component—this represents a separate serious adverse effect requiring permanent avoidance of the medication. 1

• Do not restart any contraception without ensuring adequate alternative contraceptive coverage, as the patient remains at risk for pregnancy. 1